Aroa Biosurgery's total inventories for the quarter that ended in Mar. 2026 was A$5.02 Mil. Aroa Biosurgery's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Mar. 2026 was A$6.06 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Aroa Biosurgery's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was A$0.06.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Aroa Biosurgery's Days Inventory for the
six
months ended in Mar. 2026 was 163.61.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Aroa Biosurgery's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.12.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aroa Biosurgery's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.13.
Aroa Biosurgery (ASX:ARX) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Aroa Biosurgery's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aroa Biosurgery's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Aroa Biosurgery Total Inventories Related Terms
Aroa Biosurgery Total Inventories Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Aroa Biosurgery (ASX:ARX) has a Total Inventories of A$5.02 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Total Inventories too high?
Aroa Biosurgery's current Total Inventories is A$5.02 Mil. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Total Inventories compare to ABT and SYK?
Aroa Biosurgery's Total Inventories of A$5.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Aroa Biosurgery and its competitors. Aroa Biosurgery's current Total Inventories is A$5.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Total Inventories is A$5.02 Mil. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Total Inventories is A$5.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Total Inventories: A$5.02 Mil
GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
